Clinical Trials Directory

Trials / Completed

CompletedNCT00900432

Immune Response in Peripheral Blood of Patients With Colon Cancer

Immune Studies of Peripheral Blood From Patients With Malignant Disease Gastrointestinal Tract

Status
Completed
Phase
Study type
Observational
Enrollment
67 (actual)
Sponsor
University of Arizona · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in the immune system that may help kill cancer cells. PURPOSE: This laboratory study is looking at anticancer immune responses in the peripheral blood of patients with colon cancer.

Detailed description

OBJECTIVES: * Quantify T cells specific for tumor peptides (carcinoembryonic antigen and MUC1) from the peripheral blood of patients with colon cancer. OUTLINE: This is an open-label study. Patients undergo blood collection at time of follow-up, surgery, thoracentesis, paracentesis, or leukapheresis (≤ 5 times per year). Blood is analyzed for tumor peptides (carcinoembryonic antigen and MUC1), circulating cytokines, and lymphocyte response by ELISA, ELISPOT, or intracellular flow. PROJECTED ACCRUAL: A total of 140 patients will be accrued for this study.

Conditions

Interventions

TypeNameDescription
OTHERimmunoenzyme technique
OTHERlaboratory biomarker analysis

Timeline

Start date
2004-07-01
Primary completion
2008-12-01
Completion
2008-12-01
First posted
2009-05-12
Last updated
2015-12-03

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00900432. Inclusion in this directory is not an endorsement.